QuitNic: A Pilot Randomized Controlled Trial Comparing Nicotine Vaping Products With Nicotine Replacement Therapy for Smoking Cessation Following Residential Detoxification.

Plain-language guide to PMID 32770246 (2021): pilot randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 32770246
Journal: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Year: 2021
Study type: Randomized Controlled Trial
Authors: Bonevski B et al. (13 authors)
DOI: 10.1093/ntr/ntaa143

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The QuitNic pilot trial aimed to test the feasibility of providing a nicotine vaping product (NVP) compared with combination nicotine replacement therapy (NRT) to smokers upon discharge from a smoke-free residential substance use disorder (SUD) treatment service.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

QuitNic was a pragmatic two-arm randomized controlled trial.

At discharge from residential withdrawal, 100 clients received telephone Quitline behavioral support and either 12-week supply of NRT or an NVP.

Results are reported for complete cases and for abstinence outcomes, penalized imputation results are reported where missing is assumed smoking.

What Was Measured

Topics PubMed links to this paper include Aftercare, Behavior Therapy, Counseling, Electronic Nicotine Delivery Systems, Nicotinic Agonists, Pilot Projects and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.